Table 3 Different pathologic findings as reported in the studied ROLL and WGL groups
variable | ROLL | WGL | p-value |
|---|---|---|---|
Malignant | 135(42.2%) | 159(45.4%) | |
DCIS | 24(7.5%) | 35(10.0%) | 0.13 |
IBC NST | 54(16.9%) | 76(21.7%) | 0.13 |
Invasive tubular carcinoma | 15(4.7%) | 11(3.1%) | 0.13 |
Invasive lobular carcinoma | 4(1.2%) | 9(2.6%) | 0.13 |
Post neoadjuvant therapy status for IBC NST | 38(11.9%) | 28(8.0%) | 0.13 |
Benign: | 185(57.8%) | 191(54.5%) | |
Fibroadenoma | 30(9.4%) | 36(10.3%) | 0.13 |
Granulomatous lobular mastitis | 2(0.6%) | 0(0.0%) | 0.13 |
Intraductal papilloma | 21(6.6%) | 30(8.6%) | 0.13 |
Fibrocystic disease, scleroing adenosis, ADH& PASH | 132(41.2%) | 125(35.7%) | 0.13 |